Author: Roshan ( Web Admin )

2 thoughts on “Question of the Week – 2017

  1. Can be used according to sensitivity although most do not attempt. Newer combinations are used for the treatment of CRE infections too.

  2. Theoretically we can treat ESBL infection with BL/BLI combination as ESBLs are Class A betalactamases which are inhibited by BLI. However, there is some concern that clinical outcomes in sepsis are not so good with BL/BLI when compared to carbapenems.

    As far as CRE, carbapenemases come in Class A, B and D forms and therefore BL/BLI cannot be recommended. However newer combinations such as ceftazidime-avibactam may be useful.

Comments are closed.